Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.

Journal Article (Review)

Lipoprotein (a) [Lp(a)] is a low-density, cholesterol-containing lipoprotein that differs from other low-density lipoproteins due to the presence of apolipoprotein(a) bound to its surface apolipoprotein B100. Multiple epidemiologic studies, including Mendelian Randomization studies, have demonstrated that increasing Lp(a) levels are associated with increased risk of heart disease, including atherosclerotic cardiovascular disease and calcific aortic stenosis. The risk associated with elevations in Lp(a) appears to be independent of other lipid markers. While the current treatment options for elevated Lp(a) are limited, promising new therapies are under development, leading to renewed interest in Lp(a). This review provides an overview of the biology and epidemiology of Lp(a), available outcome studies, and insights into future therapies.

Full Text

Duke Authors

Cited Authors

  • Shah, NP; Pajidipati, NJ; McGarrah, RW; Navar, AM; Vemulapalli, S; Blazing, MA; Shah, SH; Hernandez, AF; Patel, MR

Published Date

  • July 1, 2020

Published In

Volume / Issue

  • 126 /

Start / End Page

  • 94 - 102

PubMed ID

  • 32336532

Pubmed Central ID

  • 32336532

Electronic International Standard Serial Number (EISSN)

  • 1879-1913

Digital Object Identifier (DOI)

  • 10.1016/j.amjcard.2020.03.043

Language

  • eng

Conference Location

  • United States